Troglitazone, a thiazolidinedione, is a novel agent for the oral treatment of non-insulin-dependent (Type II) diabetes mellitus; it works by increasing cell sensitivity to available insulin. Previous studies have shown that rodents treated with high doses of troglitazone develop increased heart weight and increased interscapular brown fat. This study investigated cellular proliferation in heart and brown fat of troglitazone-treated mice as well as possible interactions with an angiotensin-converting enzyme inhibitor (quinipril). B6C3F 1 female mice were treated daily with either vehicle control, 125 mg/kg quinipril, 1,200 mg/kg troglitazone, or troglitazone/quinipril combination per os for up to 14 days. Four days before necropsy, mice were dosed with bromodeoxyuridine (BrdU) using osmotic pumps. Cell proliferation in heart, brown fat, and retroperitoneal white fat was investigated by means of light microscopic anti-BrdU immunolabeling techniques. Immunoelectron microscopy was used to determine the cell phenotypes and cellular distribution of BrdU label in heart and brown fat. Treatment with troglitazone for 2 wk resulted in increased heart and brown fat weights but in decreased white fat weight. Combination treatment with troglitazone and quinipril also resulted in decreased white fat weight compared with controls. Histologically, brown fat adipocytes in troglitazone-and troglitazone/quinipril-treated mice had coalescent lipid vacuoles and increased eosinophilia of the cytoplasm. White fat adipocytes in troglitazone-and troglitazone/quinipril-treated mice had decreased cell size and increased cytoplasmic eosinophilia. BrdU labeling revealed increased cell proliferation in troglitazone-treated hearts after 1 wk but did not reveal increased cell proliferation in quinipril-or troglitazone/quinipril-treated animals. Brown fat BrdU labeling after 1 wk was increased in troglitazone-and troglitazone/quinipril-treated mice. Ultrastructural anti-BrdU immunogold labeling demonstrated that troglitazone-treated heart and brown fat had greater populations of BrdU-labeled cells that were identified as endothelial cells. These results demonstrated that troglitazone-induced increased cardiac weight in mice can be prevented by quinipril and that increased cardiac weight coincides with early increased endothelial cell proliferation.
INTRODUCTION
Troglitazone is a thiazolidinedione, a new class of oral antidiabetic drugs that modifies the cellular response to insulin. These drugs effectively normalize hyperglycemia in diabetic animal models (13, 23) and in non-insulindependent diabetes mellitus (NIDDM) patients (14, 38, 42) . The mechanism of troglitazone action in not completely defined, but troglitazone enhances hepatocellular glucose utilization (7) and glycolysis (29) . The molecular target for troglitazone appears to be the nuclear peroxisomal proliferator-activated receptor-y (PPARY) (24) , which undergoes conformational changes following troglitazone binding (3) .
Treatment of normal rats and mice with troglitazone results in dose-dependent increased cardiac weight and hyperplastic interscapular brown fat (9, 17, 18, 27, 35) . The increased cardiac weight following troglitazone treatment in rodents was unsuspected because troglitazone is usually associated with decreased blood pressure in animal diabetes models (36) and NIDDM patients (32) as opposed to increased systemic blood pressure, which could lead to cardiac hypertrophy. The effect of troglitazone on cardiac cell proliferation is unknown, but increased cardiac weight is generally associated with cardiomyocyte hypertrophy and interstitial cell proliferation rather than with an exclusive cardiomyocyte hypertrophy (45) . Troglitazone-induced expansion of brown fat could be related to troglitazone-mediated PPARy activation and promotion of brown adipocyte differentiation (44) . Troglitazone increases the number of small adipocytes in obese Zucker rats (33) and also promotes adipocyte differentiation of 3T3 fibroblasts in vitro (43) .
The purpose of this study was to characterize troglitazone-induced cell proliferation in the heart and adipose tissue and to determine if an angiotensin-converting enzyme inhibitor (ACEI; quinipril) influences troglitazoneinduced cardiac cell proliferation. Clinical and animal studies indicate that ACE inhibitors prevent cardiac hypertrophy (4) , and, similarly, it was proposed that quinipril may prevent troglitazone-induced increased cardiac weight. Bromodeoxyuridine (BrdU) incorporation was used with light microscopy in order to determine rates of cell proliferation and with electron microscopy in order to determine cellular distribution of BrdU-positive nuclei in the heart and brown fat. In addition, BrdU incorporation of white fat was determined. The results of this study demonstrate that troglitazone caused increases in cardiac endothelial cell and brown fat cell proliferation but not in white fat. In the heart, troglitazone treatment increased endothelial cell proliferation with no apparent cardiomyo- (Table I) . After 1 wk of treatment, relative white fat weights decreased by 47% in troglitazone-treated mice and by 79% in troglitazone/quinipril-treated mice. At 2 wk, the relative heart (10%) and brown fat (21 %) weights were significantly increased in the troglitazone-treated mice. In addition, at 2 wk the relative white fat weights were significantly decreased in troglitazone-treated (62%) and troglitazone/quinipriltreated (66%) mice.
Pathology
At necropsy, decreased white fat was observed after 1 and 2 wk in troglitazone-treated (13-53% incidence) and troglitazone/quinipril-treated (60-64% incidence) mice. Correlating with these gross changes, the white fat adipocytes in troglitazone-and troglitazone/quinipril-treated mice had increased cytoplasmic eosinophilia and decreased cell size (Fig. lA, B) . In the troglitazone-and troglitazone/quinipril-treated mice, brown fat after 1 and 2 wk of treatment displayed coalescence of cytoplasmic lipid vacuoles into a single or a few vacuoles as well as increased eosinophilia of the remaining cytoplasm ( Fig.  2A, B) . No histologic alterations were evident in heart tissue from treated groups.
Immunohistochemistry
The group means of BrdU-positive nuclei per square millimeter in the heart, brown fat, white fat and heart capillary profiles per square millimeter are listed in Table   II . The heart tissue of troglitazone-treated mice showed an approximately 2-fold, significant increase in BrdUpositive nuclei compared with controls; however, no increase in capillary profiles per square millimeter was evident (Fig. 3) . (45) . Accurate morphometric analysis of cardiomyocyte diameter and volume was not possible in our study because hearts were not perfusion fixed.
As previously characterized, cell populations in the heart include cardiomyocytes, endothelial cells (EC), fibroblasts, pericytes, smooth muscle cells, and macrophages (30) . Results from our study indicate that cardiac interstitial cell (pericyte, fibroblast, and macrophage) proliferation occurs in both control and troglitazone-treated animals. However, the immunoelectron microscopy data clearly demonstrate that troglitazone treatment results in (20) . Apparently, the decrease in capillary density is attributable to larger cardiac muscle fiber size, which affects the relative density rather than the absolute number of capillaries.
The presence of a troglitazone-induced increase in the cell proliferation of cardiac tissue at 1 wk but not at 2 wk was surprising, considering that statistically significant heart weight increases occurred in troglitazone-treated mice at 2 wk. It is possible that the cell proliferation observed at 1 wk was necessary to provide for cardiomyocyte hypertrophy and heart weight increases manifested at 2 wk. Another plausible explanation is that the proliferation may have been pulsed or sporadic and that the 2-wk time point failed to indicate the preceding cell proliferation phase.
The mechanism of the troglitazone-induced EC proliferation in this study may be related to either direct or indirect mitogenic influences. There is very little support for a direct effect of troglitazone on EC, as several studies have shown that troglitazone or related thiazolidinediones do not have direct mitogenic effects on EC (16) or smooth muscle cells (10, 22, 28) . In fact, troglitazone inhibited basic fibroblast growth factor (bFGF)-induced EC proliferation in vitro (16) and angiotensin II-induced smooth muscle cell DNA synthesis (15 (34) or in troglitazone-treated patients (41) . In addition, enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensive patients (32) , with potential cardiovascular benefits. Also, the cardioprotective effects of troglitazone have been demonstrated in streptozotocin-induced diabetic rats (40) .
The brown adipose changes induced by troglitazone in our study are consistent with the findings of 13-wk mouse (27) , 52-wk rat (8), 13-wk rat (18) , and rodent carcinogenicity studies (17, 26) . However, brown fat changes were not noted in a 52-wk troglitazone toxicity study in cynomolgus monkeys (34) (5) .
Brown fat function consists predominantly of thermogenesis through a mitochondrial-associated uncoupling protein that oxidizes endogenous and exogenous substrates at a very high rate independent of ADP phosphorylation (19) . Brown adipocytes characteristically contain numerous small, variably sized cytoplasmic fat droplets (19) ; however, brown fat morphology varies, as is seen in cold acclimation and seasonal dependence in hibernating animals (21) . Human brown fat often has a variable morphology, ranging from unilocular to multilocular lipid distribution within the cytoplasm (21) . It has been suggested that the mediators of brown fat hyperplasia include bFGF (47) and IGF-1 (46) . It is possible that troglitazone-induced brown fat morphology shifts from multilocular to unilocular phenotype and may be related to troglitazone effects on PPARy and to the resultant upregulation of uncoupling protein (UCP-1) (39). Pioglitazone, which is also a member of the thiazolidinediones, has been known to upregulate UCP-1 in brown fat, thus driving the differentiation of preadipocytes to mature brown adipocytes in brown fat (12) . (6) .
In summary, troglitazone treatment induces increased cardiac tissue mass in mice, with a corresponding increase in EC proliferation, but it does not induce increased capillary density of the myocardium. This increase in heart weight may be dependent on angiotensin II, as evidenced by the lack of heart weight increases and similar cell proliferation in quinipril-treated and control mice. Troglitazone-induced increased cardiac weights appear to be unique to rodents, as no adverse cardiac changes in troglitazone-treated cynomolgus monkeys or human patients have been observed in other studies. Troglitazone-induced cell proliferation in brown fat was not influenced by quinipril cotreatment, as evidenced by similar increased brown fat cell proliferation in both troglitazoneand troglitazone/quinipril-treated mice.
